Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31388225 | 1.00 | MEN1 (0.55) | MEN1KMT2AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL22201436 | 0.87 | PRKCH (0.52) | MEN1KMT2AL3MBTL1HPGDSMN1; SMN2 | |
| Quinoline SCHEMBL27467667 | 0.86 | ALDH1A1 (0.50) | MEN1KMT2AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL4767456 | 0.85 | AGTR1 (0.45) | MEN1KMT2AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL7258823 | 0.85 | CYP19A1 (0.47) | MEN1KMT2AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL14727429 | 0.83 | CYP11B1 (0.57) | KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL15124692 | 0.82 | MEN1 (0.53) | MEN1KMT2AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL28619679 | 0.82 | CYP1A2 (0.44) | MEN1KMT2AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL4766591 | 0.81 | TOP1 (0.44) | SMN1; SMN2ADORA3IDO1TDO2MAPT | |
| SCHEMBL4763954 | 0.81 | NPC1 (0.58) | MEN1KMT2AHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431318-A | Organic compound, organic electroluminescent device and electronic device comprising the same | 陕西莱特光电材料股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025031012-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME, AND ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2025-02-13 | — | — | WO | disclosed |
| CN-109678798-A | A kind of synthetic method of isoquinoline compound | 湖南科技大学 | 2019-04-26 | — | — | CN | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2033654-B1 | Process for resolving a mixture of alkyl ester enantiomers using an enzyme | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2033654-B1 | Process for resolving a mixture of alkyl ester enantiomers using an enzyme | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-8034944-B2 | Benzofluoranthene compound and organic light-emitting device using the compound | CANON KABUSHIKI KAISHA (JP) | 2011-10-11 | — | — | US | disclosed |
| US-5622961-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5622962-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5578724-A | INHIBITORS OF 5-ALPHA-REDUCTASE | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-4801593-A | VIRICIDE FOR RHINITIS VIRUS CONTAINING 2-PHENYLTETRALIN DERIVATIVE | BURROUGHS WELLCOME CO. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0025598-B1 | THE USE OF 2-PHENYLTETRALIN DERIVATIVES, OR HETEROCYCLIC ANALOGUES, IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-08-01 | — | — | EP | disclosed |
| EP-0025598-A1 | The use of 2-phenyltetralin derivatives, or heterocyclic analogues, in medicine and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | disclosed |
| US-3961062-A | Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | MEN1 4790/4885KMT2A 1061/4885L3MBTL1 2556/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | MEN1 1413/4885KMT2A 1457/4885L3MBTL1 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.